Eris Lifesciences jumps 9% as Q4 FY26 profit triples

Market reaction to the results

Eris Lifesciences shares rallied after the company posted a sharp jump in consolidated earnings for the March quarter. The stock rose 8.57% to ₹1,455.25 following the announcement. In another trading snapshot cited alongside the results, the stock touched an intraday high of ₹1,504.5 and later traded around ₹1,457 on the BSE.

The move came as investors reacted to strong profit growth, stable operating profitability, and a dividend announcement for FY27. The update also provided segment-level revenue trends for the domestic branded formulations business and international operations.

Q4 FY26: Net profit surges 200.09%

For Q4 FY26, Eris Lifesciences reported consolidated net profit of ₹281.61 crore. This was up 200.09% compared with ₹93.84 crore in Q4 FY25.

Revenue growth was more modest but positive. Total revenue from operations rose 7.26% year-on-year to ₹756.56 crore in Q4 FY26.

Profit before tax rises 23.69%

Profit before tax (PBT) stood at ₹159.41 crore in Q4 FY26. This was up 23.69% from ₹128.87 crore in the same quarter last year.

The PBT growth indicates that the quarter’s operating performance and other income or cost items translated into a meaningful increase at the pre-tax line, even as revenue growth remained in single digits.

EBITDA climbs 8% and margin expands

Eris reported EBITDA of ₹274 crore in Q4 FY26, up 8% compared with ₹252 crore in the same quarter last year. EBITDA margin expanded to 36.2% in Q4 FY26 from 35.8% in Q4 FY25.

The margin expansion was modest in percentage terms, but it reflects stable operating leverage. For a branded formulations business, sustained margins at the mid-30% level are closely watched because they influence cash generation and reinvestment capacity.

Segment performance: Domestic branded formulations lead

The domestic branded formulation (DBF) business remained the key growth driver during the quarter. Revenue from DBF jumped 12% year-on-year to ₹671 crore in Q4 FY26.

In contrast, the International Business fell 8% to ₹86 crore in Q4 FY26. The split highlights the company’s continuing dependence on domestic branded formulations for both scale and growth.

Interim dividend for FY27: amount, record date, payout timeline

Alongside the results, the company declared an interim dividend of ₹7.21 per fully paid-up equity share of Re 1 each (721%) for FY27. It fixed Friday, May 29, 2026 as the record date to determine shareholder eligibility.

The company said the dividend will be paid on or before June 19, 2026. For investors, the record date and the payment deadline are the two operational dates that matter for dividend entitlement and cash receipt.

What earlier periods show: FY24 and FY25 reference points

The broader context in the provided disclosures includes a set of FY24 and FY25 financial markers. For FY24, Eris revenue rose 36.8% year-on-year to ₹2,009 crore and net profit rose 6.1% to ₹397 crore, with EBITDA margin expanding by 170 basis points to 33.6%. Net debt on March 31 was reported at ₹2,700 crore.

For FY25, another disclosure cited revenue of ₹705 crore for Q4 FY25 and FY25 revenue of ₹2,894 crore, with FY25 EBITDA of ₹1,017 crore and net debt as on 31 March at about ₹2,222 crore. These figures, presented alongside other quarterly numbers, provide a reference for how the company’s scale and profitability have evolved across years.

Acquisition backdrop and business profile

Eris Lifesciences is described as an Indian pharmaceutical company and a leading player in the domestic branded formulations market, engaged in manufacturing and marketing pharmaceutical products. The company also acquired Biocon Biologics' domestic branded formulation business for ₹1,242 crore in Q4 FY24, along with dermatology and nephrology units in Q3 FY24, as cited in the provided information.

Such acquisitions can reshape segment mix and margins, and the company has previously referenced integration progress and synergy benefits in connection with the Biocon acquisitions.

Key numbers at a glance

Dividend dates summary

Why the Q4 FY26 print matters

The Q4 FY26 update brings together three signals investors typically track in domestic branded pharma names. First is the sharp rise in consolidated net profit to ₹281.61 crore, which drove the immediate stock reaction. Second is stable operating profitability, with EBITDA margin at 36.2% versus 35.8% a year earlier.

Third is the segment divergence: DBF revenue grew 12% year-on-year to ₹671 crore while international revenue declined 8% to ₹86 crore. This makes domestic execution, brand traction, and pricing discipline central to how the quarter is read.

Conclusion

Eris Lifesciences posted a strong Q4 FY26 profit performance, supported by steady revenue growth, a slight EBITDA margin expansion, and higher domestic branded formulations revenue. The company also announced an interim dividend for FY27 with a May 29, 2026 record date and payment on or before June 19, 2026.

Investors will now track how the domestic branded formulations trajectory and international performance evolve in subsequent quarters, alongside any further updates tied to the company’s integration and business mix.